5.05 USD
+0.07 (+1.41%)
At close: Jan 30, 2026
5.15 USD
+0.1 (+1.98%)
After Hours: 1/30/2026, 8:14:49 PM
Overall RADX gets a fundamental rating of 3 out of 10. We evaluated RADX against 525 industry peers in the Biotechnology industry. The financial health of RADX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, RADX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- RADX had negative earnings in the past year.
- In the past year RADX has reported a negative cash flow from operations.
- In the past 5 years RADX always reported negative net income.
- RADX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -44.34%, RADX is in line with its industry, outperforming 55.81% of the companies in the same industry.
- RADX's Return On Equity of -85.60% is in line compared to the rest of the industry. RADX outperforms 50.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.34% | ||
| ROE | -85.6% | ||
| ROIC | N/A |
ROA(3y)-52.36%
ROA(5y)-329.25%
ROE(3y)-111.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 1.08%, RADX is doing good in the industry, outperforming 71.62% of the companies in the same industry.
- The Profit Margin and Operating Margin are not available for RADX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RADX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for RADX has been increased compared to 1 year ago.
- There is no outstanding debt for RADX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -2.26, we must say that RADX is in the distress zone and has some risk of bankruptcy.
- RADX's Altman-Z score of -2.26 is in line compared to the rest of the industry. RADX outperforms 50.10% of its industry peers.
- There is no outstanding debt for RADX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.26 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
- RADX has a Current Ratio of 2.67. This indicates that RADX is financially healthy and has no problem in meeting its short term obligations.
- RADX's Current ratio of 2.67 is on the low side compared to the rest of the industry. RADX is outperformed by 68.57% of its industry peers.
- RADX has a Quick Ratio of 2.67. This indicates that RADX is financially healthy and has no problem in meeting its short term obligations.
- RADX's Quick ratio of 2.67 is on the low side compared to the rest of the industry. RADX is outperformed by 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.67 |
3. Growth
3.1 Past
- RADX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.80%, which is quite impressive.
- Looking at the last year, RADX shows a very strong growth in Revenue. The Revenue has grown by 1114.41%.
EPS 1Y (TTM)85.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.74%
Revenue 1Y (TTM)1114.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%651.94%
3.2 Future
- The Earnings Per Share is expected to grow by 24.83% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 112.87% on average over the next years. This is a very strong growth
EPS Next Y-10.26%
EPS Next 2Y1.27%
EPS Next 3Y14.8%
EPS Next 5Y24.83%
Revenue Next Year-100%
Revenue Next 2Y42.8%
Revenue Next 3Y123.94%
Revenue Next 5Y112.87%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- RADX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year RADX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as RADX's earnings are expected to grow with 14.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.27%
EPS Next 3Y14.8%
5. Dividend
5.1 Amount
- No dividends for RADX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RADIOPHARM THERANOSTICS LTD / RADX FAQ
Can you provide the ChartMill fundamental rating for RADIOPHARM THERANOSTICS LTD?
ChartMill assigns a fundamental rating of 3 / 10 to RADX.
What is the valuation status for RADX stock?
ChartMill assigns a valuation rating of 0 / 10 to RADIOPHARM THERANOSTICS LTD (RADX). This can be considered as Overvalued.
Can you provide the profitability details for RADIOPHARM THERANOSTICS LTD?
RADIOPHARM THERANOSTICS LTD (RADX) has a profitability rating of 1 / 10.
How financially healthy is RADIOPHARM THERANOSTICS LTD?
The financial health rating of RADIOPHARM THERANOSTICS LTD (RADX) is 6 / 10.